Date, Location and Venue | 4 June 2009 | Berlin, Germany
Internationales Congress Centrum (ICC)
Hall 3 – 16.15-18.15
|
Faculty |
Chair:
|
Gianantonio Rosti, MD
University of Bologna. Bologna, Italy
|
| Speakers: |
Oliver G. Ottmann, MD
Johann Wolfgang Goethe University
Frankfurt, Germany
Simona Soverini, PhD
University of Bologna
Bologna, Italy
Pierre Laneuville, MD
McGill University
Montreal, Quebec, Canada
Francis J. Giles, MD
University of Texas,
San Antonio, Texas, United States |
|
 Agenda |
| 16:15 |
|
Pattern of Practice Question |
| 16:20 |
|
Efficacy of second generation TKIs as second line therapy for CML
Oliver G. Ottmann, MD |
| 16:40 |
|
Pattern of Practice Question |
| 16:45 |
|
BCR-ABL kinase domain mutational analysis: Biology of imatinib resistance
Simona Soverini, PhD |
| 17:00 |
|
Pattern of Practice Question |
| 17:05 |
|
Clinical relevance of BCR-ABL mutations
Pierre Laneuville, MD |
| 17:20 |
|
Interactive Clinical Case: Second line therapy for chronic phase CML: How should clinicians choose the best option?
Francis J. Giles, MD |
| 17:45 |
|
Pattern of Practice Question |
| 17:50 |
|
Newly diagnosed CML: Can we improve upon results achieved with imatinib?
Gianantonio Rosti, MD |
| 18:10 |
|
Closing Remarks |
| 18:15 |
|
Adjourn |
|
|
|
|
This satellite symposium is held in conjunction with the 14th Congress of the European Hematology Association.
|
Support | This activity is supported by Novartis.
|
|
